Becton, Dickinson and Company (NYSE:BDX) Shares Purchased by CIBC Asset Management Inc

CIBC Asset Management Inc increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,923 shares of the medical instruments supplier’s stock after purchasing an additional 2,824 shares during the period. CIBC Asset Management Inc’s holdings in Becton, Dickinson and Company were worth $13,717,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the business. PineStone Asset Management Inc. lifted its stake in Becton, Dickinson and Company by 141.6% during the second quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock worth $314,544,000 after purchasing an additional 788,735 shares during the last quarter. First Eagle Investment Management LLC raised its holdings in Becton, Dickinson and Company by 32.5% during the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after purchasing an additional 688,296 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Becton, Dickinson and Company by 8.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock worth $1,031,167,000 after buying an additional 346,720 shares during the last quarter. Magnetar Financial LLC acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at $75,493,000. Finally, Ameriprise Financial Inc. grew its position in shares of Becton, Dickinson and Company by 6.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 5,055,354 shares of the medical instruments supplier’s stock valued at $1,181,483,000 after buying an additional 302,893 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $225.15 on Friday. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. The stock has a 50 day simple moving average of $236.30 and a 200-day simple moving average of $234.99. The company has a market cap of $65.08 billion, a price-to-earnings ratio of 37.90, a price-to-earnings-growth ratio of 1.72 and a beta of 0.43. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Becton, Dickinson and Company’s revenue was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.42 earnings per share. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be issued a dividend of $1.04 per share. The ex-dividend date is Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a yield of 1.85%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s payout ratio is currently 70.03%.

Wall Street Analysts Forecast Growth

BDX has been the topic of a number of research reports. Evercore ISI raised their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price target for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Raymond James decreased their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Finally, Stifel Nicolaus boosted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.